论文部分内容阅读
目的探讨贝那普利治疗不同血管紧张素转换酶(ACE)基因型儿童原发性肾病综合征(PNS)尿蛋白的疗效的相关性。方法采用PCR方法检测68例3～12岁,病程≤2周的原发性肾病综合征(PNS,单纯性)患儿的ACE基因16内含子的I/D多态性,单用贝那普利(benazeperil)治疗,疗程为4周。比较各基因型组患儿尿蛋白定量治疗前后和治疗后下降程度的差异。结果治疗4周后,三种基因型(DD、DI、II)尿蛋白定量下降均明显于治疗前(P<0.01),DD型组的尿蛋白定量下降显著高于DI、II型组(P<0.01)。结论贝那普利治疗原发性肾病综合征(单纯性)患儿的尿蛋白,其下降程度与不同ACE基因型具有显著的相关性。
Objective To investigate the clinical efficacy of benazepril in the treatment of urinary protein in patients with primary nephrotic syndrome (PNS) with different angiotensin converting enzyme (ACE) genotypes. Methods The I / D polymorphism of ACE gene intron 16 in children with primary nephrotic syndrome (PNS) of 3 to 12 years and duration ≤ 2 weeks was detected by PCR. Treatment with benazeperil was 4 weeks. The differences of urinary protein in children with different genotypes before and after treatment and after treatment were compared. Results After 4 weeks of treatment, the quantitative decrease of urinary protein in three genotypes (DD, DI, II) was significantly lower than that before treatment (P <0.01). The quantitative decrease of urinary protein in DD group was significantly higher than that in DI group and type II group <0.01). Conclusion The decrease of urinary protein in benazepril treatment of children with primary nephrotic syndrome (simple) has a significant correlation with different ACE genotypes.